Imagine a
world without allergies
Desentum’s mission is to expand the use of allergen immunotherapy (AIT) world-wide by introducing novel, effective, safe and patient-friendly AIT products that are well-documented and approved by the regulatory authorities. Our lead development programs include treatments for birch pollen, grass pollen and peanut allergies.
Desentum’s products are investigational and not approved for marketing in any region.
Technology
Our immunotherapeutic products consist of recombinant allergens specifically modified to suppress the histamine release during the desensitization process. They can significantly reduce the risk of serious adverse effects and the time required for immunotherapy.
Desentum
Desentum is a clinical-stage biopharmaceutical company developing novel types of allergen immunotherapy products that actually change the way the immune system reacts to allergens. We have a unique technology that can lead to major improvements in the future treatment of allergies.
News
Enrolment completed in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, today announced that its...
Kutsu Desentum Oy:n ylimääräiseen yhtiökokoukseen / Summons to Extraordinary General Meeting of Desentum Oy
Ylimääräinen yhtiökokous pidetään pidetään 3.2.2026 klo 13.00 alkaen /
Extraordinary General Meeting will be held on February 3rd, 2026, at 13.00 (EET)
Dosing started in Phase 2 clinical study with DM-101PX, a novel immunotherapy for treating birch pollen allergy
First trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy.